为了治疗中风、帕金森氏病和认知衰落, 将神经科技与数字疗法相结合, MindMaze Therapeutics launched combining neurotech and digital therapies to treat stroke, Parkinson’s, and cognitive decline.

通过合并Relief Therapeutics和NeuroX Group SA而形成的MindMaze Therapeutics于2025年12月15日正式启动,在瑞士六国交易所以MMTX和美国OTCQB以RLFTF和RLFTY进行交易. MindMaze Therapeutics, formed by merging Relief Therapeutics and NeuroX Group SA, officially launched on December 15, 2025, trading on the SIX Swiss Exchange under MMTX and on the U.S. OTCQB under RLFTF and RLFTY. 该公司将数字神经治疗、药物、医疗设备、AI分析以及远程保健结合起来,为中风、帕金森氏病和认知衰落等神经疾病提供可扩展的循证治疗。 The company combines digital neurotherapeutics, pharmaceuticals, medical devices, AI analytics, and telehealth to deliver scalable, evidence-based treatments for neurological conditions like stroke, Parkinson’s, and cognitive decline. 向NeuroX股东发行了1.4亿新股,未清股总额达到约1.526亿股。 With 140 million new shares issued to NeuroX shareholders, total outstanding shares reached about 152.6 million. 该公司总部设在瑞士,目的是在老龄人口需求不断增长的情况下,在全球范围内扩大获得护理的机会。 Headquartered in Switzerland, the firm aims to expand care access globally amid rising demand from aging populations.